ARTICLE | Company News
Selten, Vivus deal
January 13, 2017 8:30 PM UTC
Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford, Calif.). Vivus will assume responsibility for future financial obligations to the university...